Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com
Update: 2025-10-29
Description
Kyverna Therapeutics' experimental treatment, KYV-101, shows promising results in Phase Two study for generalized myasthenia gravis (gMG). All patients hit key milestones in improving daily symptoms, with significant reductions in clinical scores after 24 weeks. The treatment was well-tolerated, with no severe side effects. Kyverna plans to start Phase Three trial by the end of the year, potentially setting a new standard for gMG treatment.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel




